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Abstract
Diagnosis of pneumocystosis usually relies on microscopic demonstration of Pneumocystis jirovecii in respiratory samples. Conventional
PCR can detect low levels of P. jirovecii DNA but cannot differentiate active pneumonia from colonization. In this study, we used a new
real-time quantitative PCR (qPCR) assay to identify and discriminate these entities. One hundred and sixty-three bronchoalveolar lavage
ﬂuids and 115 induced sputa were prospectively obtained from 238 consecutive immunocompromised patients presenting signs of pneu-
monia. Each patient was classiﬁed as having a high or a low probability of P. jirovecii pneumonia according to clinical and radiological pre-
sentation. Samples were processed by microscopy and by a qPCR assay amplifying the P. jirovecii mitochondrial large-subunit rRNA gene;
qPCR results were expressed as trophic form equivalents (TFEq)/mL by reference to a standard curve obtained from numbered suspen-
sions of trophic forms. From 21 samples obtained from 16 patients with a high probability of P. jirovecii pneumonia, 21 were positive by
qPCR whereas only 16 were positive by microscopy. Fungal load ranged from 134 to 1.73 · 106 TFEq/mL. Among 257 specimens sam-
pled from 222 patients with a low probability of P. jirovecii pneumonia, 222 were negative by both techniques but 35 were positive by
qPCR (0.1–1840 TFEq/mL), suggesting P. jirovecii colonization. Two cut-off values of 120 and 1900 TFEq/mL were proposed to dis-
criminate active pneumonia from colonization, with a grey zone between them. In conclusion, this qPCR assay discriminates active
pneumonia from colonization. This is particularly relevant for patient management, especially in non-human immunodeﬁciency virus (HIV)-
infected immunocompromised patients, who often present low-burden P. jirovecii infections that are not diagnosed microscopically.
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Introduction
Pneumocystis pneumonia (PCP) is an opportunistic infection
caused by the ascomycetous fungus Pneumocystis jirovecii [1].
Human immunodeﬁciency virus (HIV)-infected individuals with
low CD4 counts are at considerable risk of developing PCP.
Despite the extensive use of co-trimoxazole prophylaxis and
marked advances in the control of HIV infection, resulting in
immune reconstitution, PCP remains one of the most preva-
lent infections in patients with AIDS [2]. PCP also occurs in
non-HIV-infected immunocompromised (IC) patients, includ-
ing individuals receiving immunosuppressive medication for
autoimmune or inﬂammatory diseases, patients with haemato-
logical or solid malignancies, and transplant recipients [2–7].
In non-HIV-infected IC patients, PCP is typically more acute
and severe than in patients with AIDS. Overall, PCP carries a
mortality rate of 35–55% in patients without AIDS [8], as
compared with 10–20% in patients with AIDS [9].
Diagnosis of pneumocystosis usually relies on microscopic
demonstration of P. jirovecii in bronchoalveolar lavage (BAL)
ﬂuid or induced sputum samples by the use of staining
methods. However, the lack of sensitivity of microscopic
methods, owing to the low burden of P. jirovecii in non-HIV-
infected IC patients, has justiﬁed the increasing use of
PCR-based methods for diagnosis [10]. These methods also
revealed the possibility of P. jirovecii lung colonization in HIV-
infected and non-HIV-infected IC patients, deﬁned as the
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detection of Pneumocystis organisms or their DNA in pulmo-
nary specimens from individuals without clinical signs or
symptoms of PCP [11–16].
Conventional PCR methods can detect low levels of P. ji-
rovecii DNA, but are not quantitative and cannot differentiate
PCP from colonization. Real-time quantitative PCR (qPCR), a
more appropriate method for DNA quantiﬁcation, has been
developed for the diagnosis of PCP [17–20]. However, inter-
pretation of fungal burden estimates by qPCR remains puz-
zling with regard to patient management.
In this study, we aimed to assess the ability of a new
qPCR method to discriminate PCP from P. jirovecii coloniza-
tion in non-HIV-infected and HIV-infected IC patients.
Materials and Methods
Patients and clinical samples
Samples were prospectively collected during a 7-month per-
iod from 238 consecutive IC patients, for whom a search for
P. jirovecii was performed in a context of undetermined pneu-
monia. They consisted of 163 BAL ﬂuids and 115 induced
sputa (IS). Patients’ clinical characteristics are presented in
Table 1. Sixty-nine patients were HIV-infected and 169 were
non-HIV-infected IC patients.
Fibreoptic bronchoscopy was performed after patients
gave their informed consent. The site of BAL was guided by
lung high-resolution computed tomography, and BAL was
performed with four 50-mL aliquots of sterile saline solution
following a standardized protocol. IS were obtained with the
help of experienced respiratory physiotherapists.
Clinical probability of PCP
As no international standardized score is available to classify
patients for the diagnosis of PCP, we estimated the probabil-
ity of PCP for each patient and allocated them to high-proba-
bility and low-probability groups. According to well-known
risk factors for PCP and features suggesting PCP in HIV-
infected and non-HIV-infected IC patients [5,21], the follow-
ing data were recorded: type of immunodeﬁciency, long-term
steroid therapy, immunosuppressive therapy, pneumocystosis
prophylaxis, hypoxaemia, chest radiograph ﬁndings, high-res-
olution computed tomography scan ﬁndings, microscopic
detection of Pneumocystis, other microbiological recovery on
respiratory samples, aetiological treatment and favourable
outcome after 14 days, and ﬁnal diagnosis of the episode
retained by the physician. Patient assignation was performed
independently by two physicians, without knowledge of the
results of qPCR.
Specimen processing and analysis
Respiratory specimens were centrifuged at 2800 g for
10 min. Part of the resuspended pellet (about 200 lL) was
used for microscopic methods, and 200 lL was used for
PCR. DNA extraction was performed by using a QIAamp
DNA Mini kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions.
Microscopy diagnosis
Fifty to 75 lL of the resuspended pellet diluted in phos-
phate-buffered saline was cytocentrifuged at 1100 g for
5 min on each of three microscopy slides. The ﬁrst slide was
stained with Giemsa, and the second one was subjected to
an indirect immunoﬂuorescence (IIF) assay (Monoﬂuo kit
Pneumocystis; Bio-Rad, Marnes-la-Coquette, France). Both
smears were examined by two experienced microscopists
for the demonstration of cysts and/or trophic forms. In a
few cases of negative microscopy results in patients present-
ing several other features in favour of an ongoing PCP, the
third slide was subjected to a direct immunoﬂuorescence
assay (Monoﬂuo P. jirovecii IFA test kit; Bio-Rad) and exam-
ined for the presence of trophic forms and cysts.
Real-time PCR assay
The real-time PCR assay developed for this study ampliﬁes a
121-bp fragment of the P. jirovecii mitochondrial large-subunit
rRNA gene. The primers PjF1 (5¢-CTGTTTCCCTTTCGAC
TATCTACCTT-3¢) and PjR1 (5¢-CACTGAATATCTCGAGG
GAGTATGAA-3¢) and the TaqMan-MGB probe PjSL (5¢-
TCGCACATAGTCTGATTAT-3¢) were designed by using
Primer Express software (Applied Biosystems, Foster City,
CA, USA). The qPCR assay was performed on an Applied
TABLE 1. Patient characteristics
Characteristic All patients
(n = 238)
PCP patients
(n = 16)
Age (years), median (range) 48 (7–88) 42 (22–82)
Sex, male/female 160/78 12/4
Underlying diseases
HIV infection 69 9
Haematological malignancies
(including 35 allogeneic HSCT)
Lymphoma 47 2
Chronic lymphocytic leukaemia 12 0
Acute lymphoblastic leukaemia 7 0
Acute myeloid leukaemia 24 0
Myeloproliferative syndrome 8 0
Myelodysplasia 8 0
Myeloma 9 0
Haemolytic anaemia 3 1
Solid organ transplantation
Kidney transplantation 14 2
Kidney + pancreas transplantation 1 1
Solid malignancies 14 0
Autoimmune diseases with
immunosuppressive regimens
22 1
HIV, human immunodeﬁciency virus; HSCT, haematopoietic stem cell transplan-
tation; PCP, Pneumocystis pneumonia.
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Biosystems 7500 PCR system, in a ﬁnal volume of 25 lL, by
using the TaqMan Universal Master Mix (Applied Biosys-
tems), with 0.4 lM each primer, 0.2 lM probe, and 5 lL of
extracted DNA sample. After 2 min at 50C and 10 min at
95C, ampliﬁcation consisted of 45 cycles of 15 s of denatur-
ation at 95C followed by 1 min of annealing and extension
at 60C. All samples were tested in duplicate. Each qPCR
run comprised ﬁve serial ten-fold dilutions of a calibrated
P. jirovecii DNA solution prepared from a suspension of P. ji-
rovecii (human BAL) in which trophic forms were counted
microscopically by two independent expert microscopists.
These dilutions were used to establish a qPCR calibration
curve giving the correspondence between cycle threshold
values and the number of trophic forms per millilitre. By
interpolation, this allowed expression of the results in tro-
phic form equivalents (TFEq)/mL. Each clinical sample was
tested both in the reaction mixture described above and in a
second reaction mixture additionally containing TaqMan
Exogenous Internal Positive Control reagents (Applied Bio-
systems), in order to search for the presence of PCR inhibi-
tors. When the cycle threshold value of the Internal Positive
Control was increased by more than three in the presence
of the clinical sample, the sample was ten-fold diluted and
retested.
Statistical analysis
Low-probability and high-probability groups were compared
by using a two-tailed Student’s t-test. A receiver operator
characteristic (ROC) curve, constructed with GraphPad
Prism version 5.01 for Windows (GraphPad Software, San
Diego, CA, USA), was used to deﬁne cut-off values.
Results
Clinical probability of PCP classiﬁcation
Sixteen patients (21 samples) were placed in the high-proba-
bility group and 222 patients (257 samples) in the low-proba-
bility group. Table 2 shows the main characteristics of
patients with a high probability of PCP. In this group, Pneu-
mocystis was not detected in the pulmonary samples from
three patients (nos. 5, 7, and 9) by IIF and Giemsa staining;
however, a few trophic forms were shown by microscopic
examination of an additional smear, using the direct immuno-
ﬂuorescence test. None of the patients with a low probabil-
ity of PCP had a positive IIF test result.
Real-time PCR assay results
Fifty-six of 278 (20.1%) respiratory samples (30 BAL ﬂuids
and 26 IS) were positive by qPCR; 24 were collected from
HIV-infected patients and 32 from non-HIV-infected IC
patients. All 21 samples collected from 16 high-probability
PCP patients were qPCR-positive, with the fungal burden in
samples ranging from 134 to 1.73 · 106 TFEq/mL (Table 2).
Thirty-ﬁve of 257 (12.9%) samples collected from 222 low-
probability PCP patients were qPCR-positive, with the fungal
burden ranging from 0.1 to 1840 TFEq/mL. These 35 samples
were collected from nine HIV-infected and 21 non-HIV-
infected IC patients; none of the 30 patients received anti-
Pneumocystis treatment with co-trimoxazole. For the nine
HIV-infected patients, the ﬁnal diagnosis of the episode was
cerebral toxoplasmosis in two cases, tuberculosis in one
case, ﬂu syndrome in one case, probable bacterial pneumonia
in three cases, lymphoid interstitial pneumonia in one case,
and complication of haemorrhagic rectocolitis in one case.
For the 21 non-HIV-infected IC patients, the ﬁnal diagnosis
of the episode was microbiologically documented bacterial
pneumonia in ﬁve cases, probable bacterial pneumonia in six
cases, viral pneumonia in one case, obliterative bronchiolitis
in one case, complication of sarcoidosis in four cases, idio-
pathic pulmonary ﬁbrosis in one case, drug-induced pneumo-
nitis in one case, hypersensitivity pneumonitis in one case,
and lymphoma progression in one case.
PCR inhibitors were detected in 12 samples (4.3%): in all
12 cases, a ten-fold dilution of the DNA extract was sufﬁ-
cient to remove PCR inhibitors.
P. jirovecii DNA quantiﬁcation among groups of samples and
patients
The results of qPCR in BAL ﬂuids and IS are presented in
Fig. 1a. P. jirovecii fungal burdens were signiﬁcantly higher in
high-probability PCP patients than in low-probability PCP
patients (p <0.0001). This difference was signiﬁcant for BAL
ﬂuids (p 0.0056) and for IS (p 0.0079). Within the high-prob-
ability PCP group and the low-probability PCP group, fungal
burdens were not signiﬁcantly different between BAL ﬂuids
and IS (p 0.79 and p 0.54). ROC curve analysis gave an area
under the curve of 0.99 (Fig. 2), conﬁrming the ability of
qPCR to discriminate PCP from colonization (p <0.0001).
Fungal burdens in HIV-infected and non-HIV-infected IC
patients are presented in Fig. 1b. In the high-probability PCP
group, but not in the low-probability PCP group, fungal bur-
dens were signiﬁcantly higher in HIV-infected patients than in
non-HIV-infected patients (p 0.0048).
Cut-off value and colonization
Differences between fungal burdens in the patient groups
allowed the determination of two cut-off values for discrimi-
nation of PCP from colonization, with a grey zone between
the two cut-off values (Table 3). Estimated cut-off values
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were 1900 and 120 TFEq/mL, respectively. With the lower
cut-off value, the sensitivity and speciﬁcity of qPCR for diag-
nosis of PCP were 100% and 96.9%, respectively. With the
upper cut-off value, the sensitivity and speciﬁcity were 85.7%
and 100%, respectively (Fig. 2). With both cut-off values, the
positive predictive value was 100% for samples quantiﬁed as
>1900 TFEq/mL and the negative predictive value was 100%
for samples quantiﬁed as <120 TFEq/mL. Accordingly, we
could ﬁnally provide a deﬁnitive interpretation of qPCR
results for 96% (267/278) of samples (Table 3). A fungal load
>1900 TFEq/mL allowed us to conclude that there was
ongoing PCP in 18 samples (6.5%). A fungal load <120 TFEq/
mL was in favour of colonization in 27 samples (9.7%). A
negative qPCR result ruled out the diagnosis of PCP or colo-
nization in 222 samples (79.9%). For the 11 remaining sam-
ples (3.9%), for which fungal load was in the grey zone (‡120
and £1900 TFEq/mL), the patient’s Pneumocystis infection sta-
tus was undetermined.
Discussion
The reference method for diagnosis of PCP is microscopic
identiﬁcation of P. jirovecii, which demonstrates either trophic
forms or cysts in respiratory samples. Since the 1990s, PCR
has markedly improved the sensitivity of detection, revealing
a new population of individuals in which detectable Pneumo-
cystis DNA is present, but few or no organisms are visualized
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FIG. 1. Pneumocystis jirovecii DNA quantiﬁcation by real-time PCR
according to the clinical probability of Pneumocystis pneumonia (PCP)
in induced sputa (IS) and bronchoalveolar lavage (BAL) samples (a)
and in human immunodeﬁciency virus (HIV)-infected and non-HIV-
infected immunocompromised patients (b). Thick horizontal bars
represent median values. HP, high probability; LP, low probability;
TFEq, trophic form equivalents.
FIG. 2. Receiver operator characteristic curve of real-time PCR
for Pneumocystis pneumonia (PCP) diagnosis. TFEq, trophic form
equivalents.
TABLE 3. Results of the real-time PCR assay for the 278
respiratory samples
Samples (%)
HP of PCP (n = 21),
no. (%)
LP of PCP
(n = 257), no. (%)
HIV
(n = 12)
Non-HIV
(n = 9)
HIV
(n = 69)
Non-HIV
(n = 188)
Positive qPCR (n = 56) 12 (100) 9 (100) 12 (17.4) 23 (12.2)
Quantiﬁcation
>1900 TFEq/mL (upper
cut-off value)
10 (83.3) 8 (88.9) 0 0
120–1900 TFEq/mL
(grey zone)
2 (16.7) 1 (11.1) 4 (5.8) 4 (2.1)
<120 TFEq/mL (lower
cut-off value)
0 0 8 (11.6) 19 (10.1)
HIV, human immunodeﬁciency virus; HP, high probability; LP, low probability;
PCP, Pneumocystis pneumonia; qPCR, quantitative PCR; TFEq, trophic form
equivalents.
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[13]. Indeed, the risk of false-positivity has been suggested,
but it has been dramatically reduced with one-step process-
ing techniques such as real-time PCR, which greatly limit
specimen processing and avoid the risk of DNA carryover.
The terms colonization, asymptomatic infection and subclini-
cal infection have been used to describe the presence of P. ji-
rovecii DNA in a host without the occurrence of clinical
pneumonia [13], but, up to now, there has been no clear
biological discrimination between colonization and disease.
Here, we show in a large cohort of immunocompromised
patients that this discrimination can be based on the estima-
tion of fungal burdens in BAL ﬂuids or IS with the use of
real-time qPCR. This assumption is based on a prospective
study performed in HIV-infected and non-HIV-infected
patients in whom the high or low probability of PCP was
estimated independently of qPCR tests performed on BAL
ﬂuids and IS.
Marked differences were found between the two groups
of patients. The high-probability PCP group was character-
ized by a positive qPCR result, with high fungal burdens, and
by the presence of P. jirovecii on IIF smears in 81.3% of
patients. In contrast, no low-probability PCP patients had
P. jirovecii by microscopy, and only 13.5% of them were
qPCR-positive. Interestingly, there was no signiﬁcant differ-
ence in fungal DNA load between IS and BAL ﬂuid samples
in the two groups of PCP patients, underlining the marked
potential of qPCR on IS for the diagnosis of PCP [20]; how-
ever, as both IS and BAL ﬂuids could be sampled in only ﬁve
patients, this assertion has to be conﬁrmed.
The sensitivity and speciﬁcity of PCR on BAL ﬂuids or IS
for diagnosis and for discrimination between PCP and coloni-
zation were estimated with different qPCR cut-off values. As
there was no signiﬁcant difference in fungal DNA load
between IS and BAL ﬂuid samples, similar cut-offs were
applicable for BAL ﬂuid and IS samples. A single cut-off value
calculated from the ROC curve (510 TFEq/mL) would lead
to 90.5% sensitivity and 98.4% speciﬁcity, and consequently
1.6% false-positive and 9.5% false-negative results for the
diagnosis of PCP. For this reason, we determined two cut-
off values giving 100% positive and negative predictive values
for quantiﬁcation as >1900 and <120 TFEq/mL, respectively.
A limited number of samples quantiﬁed within the grey zone
(‡120 and £1900 TFEq/mL) were considered to be undeter-
mined.
The quantitative results highlighted some differences
between P. jirovecii infection in HIV-infected and non-HIV-
infected IC patients. In contrast to the known higher severity
and mortality of PCP in non-HIV-infected IC patients than in
HIV-infected patients [22], we found signiﬁcantly higher fun-
gal burdens in BAL ﬂuids and IS from HIV-infected patients
than in those from non-HIV-infected IC patients. This con-
ﬁrms previous microscopic observations [23]. The reasons
for this difference are unclear, but it might reﬂect distinct
pathogenesis in the two populations. Indeed, common symp-
toms of PCP in HIV-infected patients include the subtle
onset of progressive dyspnoea, non-productive cough, and
low-grade fever, whereas non-HIV-infected IC patients with
PCP typically present more acutely, with an abrupt onset of
respiratory insufﬁciency, and have a poorer prognosis [1].
The signiﬁcantly increased number of Pneumocystis organisms
in the lungs of patients with AIDS and PCP has also been
associated with a smaller number of inﬂammatory cells
recovered in BAL ﬂuids, which correlates with better oxy-
genation and survival than in non-HIV-infected IC patients
with PCP [1,23].
We also conﬁrmed the high rate of colonization among
HIV-infected and non-HIV-infected IC patients, which was
demonstrated in 15.0% and 13.0% of our patients, respec-
tively. Such percentages are in the range of carriage reported
in other studies [13,14]. However, the pathogenic conse-
quences of colonization remain debated. It is estimated that
colonization could represent an early stage of disease pro-
gression [14], and it has been shown that it is a comorbidity
factor in obstructive pulmonary diseases [24–26]. The poten-
tial evolution of colonization towards PCP is well established
in animal models, in which administration of steroids pro-
gressively reactivates a latent Pneumocystis infection [27]. In
humans, data on the risk of progression to pneumonia for
colonized patients remain limited. This risk was found to be
low in HIV-infected patients [15], and has occasionally been
reported in other IC patients [16]. In the face of this poten-
tial risk of PCP, there is no clear recommendation for pro-
phylaxis or empirical therapy in colonized patients. Initiating
prophylaxis in cases of colonization could be proposed for
patients treated with immunosuppressive therapy [6], but
this should be balanced with the potential risk of long-term
administration of drugs in patients who might have a very
limited risk of PCP. In high-probability PCP patients with high
parasite burdens, treatment and then prophylaxis should
obviously be prescribed, whereas low-probability PCP
patients with low P. jirovecii burdens would not be treated
[28]. Treatment or prophylaxis in intermediate cases pre-
senting uncertainties on diagnosis could be considered. We
suggest that high-probability PCP patients with P. jirovecii bur-
dens in the grey zone could be treated, whereas those with
a low probability of infection could be resampled for IS and
followed by biological blood markers such as b-D-glucan [29],
and might receive prophylaxis but not be treated. In these
patients, oral washes could also be proposed in the follow-
up as a non-invasive method for the diagnosis of PCP [30].
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We conclude that the new real-time PCR assay developed
here proved to be sensitive for the diagnosis of pneumocys-
tosis, and represents a valuable tool with which to distinguish
active P. jirovecii pneumonia from colonization in the setting
of an aetiological diagnosis of pneumonia. It is particularly
relevant in non-HIV-infected immunocompromised patients,
who are susceptible to the development of low-burden P. ji-
rovecii infections that are not detected by direct microscopic
examination.
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